HK Stock Market Move | CUTIA-B(02487) surged more than 3%. CU-20101 (injectable type A botulinum toxin) completed Phase III clinical trials in China.

13:37 13/04/2026

Kodiv-B (02487) went up by more than 3%, as of the time of writing, it increased by 3.25% to 4.76 Hong Kong dollars, with a turnover of 409,900 Hong Kong dollars.

CUTIA-B (02487) rose more than 3%, as of the time of publication, it rose by 3.25% to HK$4.76, with a turnover of HK$409,900. On the news front, Kedi announced today that the group has completed the phase III clinical trial of CU-20101 (botulinum toxin type A for injection) for improving moderate to severe glabellar lines in China. The clinical trial aims to evaluate the effectiveness and safety of single and repeated injections of CU-20101 in treating moderate to severe glabellar lines, with a comparator drug, BOTOX, used as a control. The clinical trial completed the exit of all subjects in November 2025 and locked the database in January 2026, with positive top-line results obtained.

On May 14th, 59.69 million Hong Kong dollars were used to repurchase 200,000 shares.

JF SMARTINVEST (09636) spent 3.5158 million Hong Kong dollars on May 14 to repurchase 10.31 thousand shares.

ZERO2IPO (01945) spent 69,000 Hong Kong dollars to repurchase 39,600 shares on May 14th.

On May 14th, 59.69 million Hong Kong dollars were used to repurchase 200,000 shares.

JF SMARTINVEST (09636) spent 3.5158 million Hong Kong dollars on May 14 to repurchase 10.31 thousand shares.

ZERO2IPO (01945) spent 69,000 Hong Kong dollars to repurchase 39,600 shares on May 14th.